Mashup Score:55
www.kitepharma.comPress Releases | Kite Pharma - 5 days
Mashup Score:55
# lymsm
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell...
-
Kite just announced a significant overall survival benefit (!!!) of axi-cel from the ZUMA-7 randomized trial as compared to ASCT in second-line high-risk DLBCL. Hoping to see the data at #ASCO23. #lymsm #celltherapy HT @Eddie_Cliff https://t.co/JRA91XNj3h https://t.co/JRA91XNj3h - view on twitter
Mashup Score:50
American Society of HematologyCAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? - 2 days
Mashup Score:50
Chimeric antigen receptor (CAR) T-cell therapy is standard for patients with large B-cell lymphoma following failure of autologous stem cell transplant (SCT)....
-
Since 1995, the standard for fit patients with DLBCL relapsed after or refractory to initial therapy has been chemo/AutoSCT. 28 years later, we finally have a change to the treatment algorithm. #lymsm https://t.co/Uf3kiTQcbo - view on twitter
More coverage:
#lymsm
Mashup Score:30
JAMA NetworkThis nonrandomized clinical trial investigates the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide chemotherapy and evaluates the response rate of patients with relapsed...
-
Pembrolizumab + Ifosfamide, Carboplatin & Etoposide [ICE] Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: Multi-institutional Phase 2 Investigator-Initiated Non-RCT [Mar 16, 2023] Bryan et al. @JAMAOnc https://t.co/KXrYTyuQH4 #NCT03077828 #lymsm - view on twitter
Mashup Score:29
American Society of HematologyUsing 3 illustrative cases, Chaer et al discuss the options for the prevention and therapy of COVID-19 infection in patients with hematologic malignancies and...
-
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies [Aug 18, 2022] @FirasElChaer , Auletta, @ChemalyRoy @BloodJournal https://t.co/JIfU1A6USH #bmtsm #CARTcell #leusm #lymsm #mmsm #mpnsm https://t.co/JIfU1A6USH - view on twitter
In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of...
-
@FrontiersIn | Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular #lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi @FIL_Onlus #lymsm https://t.co/t4gZdiUSsi - view on twitter
Mashup Score:12
American Society of HematologyConcurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma - 1 week
Mashup Score:12
Key Points. Concurrent pembrolizumab and AVD was safe and effective in untreated Hodgkin lymphoma without clinically significant treatment delays.PET CR rates...
-
More PD1 data - this time frontline. • lynch et al • concurrent Pembro-AVD 1L cHL • ph2, 30 pts, mix of stage • 2y PFS / OS: 97% / 100% • 3 G3-4 immune related-reactions • ctDNA maybe better response determinant than PET Terrific data. #lymsm https://t.co/iddHPp2Pgv - view on twitter
More coverage:
#lymsm
Mashup Score:8
JAMA NetworkThis nonrandomized clinical trial investigates the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide chemotherapy and evaluates the response rate of patients with relapsed...
-
We had Pembro-GVD, then Nivo-ICE and now we have Pembro-ICE! • PhII, 37 eval pts, R/R cHL • CRR 86.5% • 2y PFS / OS: 87.2% / 95.1% • stem cell mobilisation fine • Locke et al V nice data. Didn’t see engraftment syndrome rates? #lymsm https://t.co/4jjip95h1d - view on twitter
More coverage:
#lymsm
Mashup Score:7
American Association for Cancer ResearchPatients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 - 6 days
Mashup Score:7
Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients...
-
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR https://t.co/IMEbvgZafi #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm https://t.co/IMEbvgZafi - view on twitter
Mashup Score:6
American Association for Cancer ResearchPatients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 - 5 days
Mashup Score:6
Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients...
-
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR https://t.co/IMEbvgZafi #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm https://t.co/IMEbvgZafi - view on twitter
Find recent Kite press releases...
Axi-Cel Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma - ZUMA7 @KitePharma #CARTcells #lymsm https://t.co/JKyDm56taK - view on twitter